Abstract #4033
Novel persistent tumor index to predict survival in pediatric high-grade gliomas treated with immunovirotherapy
Asim K Bag1, Joseph Holtrop1, Silu Zhang1, Matthew A Scoggins1, Yimei Li2, Tushar Patni2, Richard J Whitley3, G Yancey Gillespie4, James M Markert4, John B Fiveash5, Rong Li6, Joshua D Bernstock7,8,9, James Johnston4, and Gregory K Friedman3,4
1Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, United States, 2Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, United States, 3Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States, 4Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, United States, 5Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States, 6Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States, 7Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, United States, 8Department of Neurosurgery, Boston Children's Hospital, Boston, MA, United States, 9Department of Neurosurgery, Harvard Medical School, Boston, MA, United States
Synopsis
Early indicators of the response to imunovirotherapy are currently limited due to the novelty of the therapies and unpredictability of responses. We propose using the persistent tumor index (PTI) derived from diffusion and perfusion MRI as a predictor of treatment response. In 10 high grade glioma patients treated with imunovirotherapy, only the baseline PTI measure was associated with progression free survival whereas other known imaging biomarkers of survival were not.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
